Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer
Authors:
- 12 October 2021
- journal article
- letter
- Published by Elsevier in Cancer Cell
- Vol. 39 (11) , 1445-1447
Abstract
No abstract availableFunding Information
- Cancer Research UK
This publication has 6 references indexed in Scilit:
- Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignanciesCancer Cell, 2021
- Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancerCancer Cell, 2021
- Seroconversion rates following COVID-19 vaccination among patients with cancerCancer Cell, 2021
- Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational studyThe Lancet Oncology, 2021
- Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer PatientsCancer Cell, 2021
- COVID-19 and Cancer: Current Challenges and PerspectivesCancer Cell, 2020